4.2 Article

Racial Differences in the Presentation and Outcomes of Chronic Lymphocytic Leukemia and Variants in the United States

Journal

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
Volume 11, Issue 6, Pages 498-506

Publisher

CIG MEDIA GROUP, LP
DOI: 10.1016/j.clml.2011.07.002

Keywords

Chronic lymphocytic leukemia; Incidence; Prolymphocytic leukemia; Race; SEER Program; Survival

Ask authors/readers for more resources

Using population-based cancer registries data, we examined incidence and survival patterns of chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL), and prolymphocytic leukemia (PLL) patients. Blacks with CLL/SLL present at younger age, more advanced stage, and have inferior survival compared to Whites. Male gender and black race predicted worse survival among CLL patients, but had lesser impact on PLL outcomes. Background: Chronic lymphocytic leukemia (CLL) is the most common form of adult leukemia in the United States, and prolymphocytic leukemia (PLL) is a related, rare chronic lymphoproliferative disorder. Methods: Using the United States Surveillance, Epidemiology and End Results (SEER) data from 13 registries, we examined differences in incidence and survival for CLL, small lymphocytic lymphoma (SLL) and PLL by race. International Classification of Diseases for Oncology 3(rd) edition histology codes 9670, 9823, and 9632-34 were used to identify cases. Results: From 1992 to 2007, 30,622 cases of CLL/SLL and 268 cases of PLL were recorded. Males had higher incidence than females (male-to-female incidence rate ratio CLL/SLL 1.89, 95% confidence interval (CI) 1.85-1.94 and PLL 2.47, 95% CI 1.90-3.20). Black patients were diagnosed at younger age compared to white patients (mean age at diagnosis for white versus black patients for CLL/SLL, 70 versus 67 years, P < .001; for PLL, 71 versus 61 years, P < .001). Greater proportion of black patients with SLL presented with B symptoms, extranodal primary site, and advanced disease compared to white patients (P = .003, P = .012, and P = .009 respectively). White patients with CLL/SLL had better survival rates than black patients (5-year relative survival rate 77.1% versus 63.9%, P < .01). In univariate Cox regression models, black race, male gender, age at diagnosis > 65 years, advanced stage, and B-symptoms were predictors of worse survival (P < .01) among CLL/SLL patients. Conclusions: Black patients with CLL/SLL and PLL present at younger age and black patients with CLL/SLL have worse survival than white patients. Epidemiological studies examining the biological variants of these diseases in concert with race are needed to elucidate the etiology of these disparities.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Letter Hematology

Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib

Preetesh Jain, Rashmi Kanagal-Shamanna, Shaojun Zhang, Chi Young OK, Lucy Navsaria, Loretta Nastoupil, Hun Ju Lee, Guilin Tang, C. Cameron Yin, Maria Badillo, Ranjit Nair, Shaoying Li, Keyur M. Patel, Christopher Flowers, Francisco Vega, Linghua Wang, Michael L. Wang

AMERICAN JOURNAL OF HEMATOLOGY (2021)

Review Oncology

Primary Mediastinal B Cell Lymphoma in the Positron-Emission Tomography Era Executive Summary of the American Radium Society Appropriate Use Criteria

Bradford S. Hoppe, Ranjana Advani, Sarah A. Milgrom, Richard L. Bakst, Leslie K. Ballas, Bouthaina S. Dabaja, Christopher R. Flowers, Chul S. Ha, David B. Mansur, Monika L. Metzger, Chelsea C. Pinnix, John P. Plastaras, Kenneth B. Roberts, Sonali M. Smith, Stephanie A. Terezakis, Jessica M. Kirwan, Louis S. Constine

Summary: The purpose of the study was to develop evidence-based guidelines for treating primary mediastinal B cell lymphoma (PMBCL) in adolescents and young adults. Through a systematic review and Delphi framework, consensus guidelines were developed based on the 5-point Deauville scale for EOC PET response. The guidelines cover various treatment approaches, including chemoimmunotherapy regimens, consolidative radiation therapy, and adaptive approaches based on EOC PET/CT response.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2021)

Article Oncology

Prognostic value of disease distribution in secondary central nervous system diffuse large B cell lymphoma treated with radiation therapy

Karine A. Al Feghali, Penny Fang, Maria Gule-Monroe, Sarah Milgrom, Joseph D. Khoury, Jillian R. Gunther, Tommy Sheu, Ranjit Nair, Sairah Ahmed, Raphael Steiner, Paolo Strati, Elizabeth J. Shpall, Yago L. Nieto, Chitra Hosing, Loretta J. Nastoupil, Jason R. Westin, Sattva S. Neelapu, Nathan Fowler, Christopher Flowers, Chelsea C. Pinnix, Bouthaina S. Dabaja

Summary: The distribution of baseline disease can impact the prognosis of patients with secondary CNS DLBCL, with those having localized disease potentially benefiting from stem cell transplantation post-Radiation Therapy. Receipt of SCT, response after RT, and presence of localized disease were associated with improved overall survival and CNS-disease-free survival.

LEUKEMIA & LYMPHOMA (2021)

Article Multidisciplinary Sciences

Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma

Shaojun Zhang, Vivian Changying Jiang, Guangchun Han, Dapeng Hao, Junwei Lian, Yang Liu, Rongjia Zhang, Joseph McIntosh, Ruiping Wang, Minghao Dang, Enyu Dai, Yuanxin Wang, David Santos, Maria Badillo, Angela Leeming, Zhihong Chen, Kimberly Hartig, John Bigcal, Jia Zhou, Rashmi Kanagal-Shamanna, Chi Young Ok, Hun Lee, Raphael E. Steiner, Jianhua Zhang, Xingzhi Song, Ranjit Nair, Sairah Ahmed, Alma Rodriquez, Selvi Thirumurthi, Preetesh Jain, Nicolaus Wagner-Bartak, Holly Hill, Krystle Nomie, Christopher Flowers, Andrew Futreal, Linghua Wang, Michael Wang

Summary: This study investigates the mechanisms driving resistance to treatment in mantle cell lymphoma (MCL) by analyzing the cellular and molecular heterogeneity within patients using single-cell sequencing. The researchers found temporal activation of cancer hallmark pathways and acquisition of 17q in refractory MCL, leading to upregulation of BIRC5/survivin expression. They demonstrate that targeting BIRC5 results in effective tumor inhibition in preclinical models and also identify changes in the tumor microenvironment in refractory MCL, including decreased CD8+ T cells and aberrant cell-to-cell communication networks.

NATURE COMMUNICATIONS (2021)

Article Immunology

Influenza Vaccination Rates Among Patients With a History of Cancer: Analysis of the National Health Interview Survey

Andres Chang, Mallory K. Ellingson, Christopher R. Flowers, Robert A. Bednarczyk

Summary: The study found that vaccination rates for influenza are higher in cancer patients, but there is still room for improvement. Men and women with solid tumors and hematological malignancies have significantly higher vaccination rates compared to those without cancer, emphasizing the need for enhancing vaccine compliance to prevent complications.

OPEN FORUM INFECTIOUS DISEASES (2021)

Article Hematology

Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials

Carla Casulo, Jesse G. Dixon, Fang-Shu Ou, Eva Hoster, Bruce A. Peterson, Howard S. Hochster, Pauline Brice, Marco Ladetto, Wolfgang Hiddemann, Robert Marcus, Eva Kimby, Michael Herold, Tina Nielsen, Franck Morschhauser, Mathias Rummel, Anton Hagenbeek, Umberto Vitolo, Gilles A. Salles, Qian Shi, Christopher R. Flowers

Summary: Limited data exists on the clinical features and outcomes of elderly patients with follicular lymphoma (FL). In a pooled analysis of individual patient data from first-line randomized controlled trials, age over 70 was a significant predictor of overall survival and progression-free survival in FL patients. However, age alone should not exclude elderly patients from standard treatments or clinical trials.

BLOOD ADVANCES (2021)

Article Hematology

Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era

Reem Karmali, Jeffrey M. Switchenko, Subir Goyal, Krithika Shanmugasundaram, Michael C. Churnetski, Bhaskar Kolla, Veronika Bachanova, James N. Gerson, Stefan K. Barta, Max J. Gordon, Alexey Danilov, Natalie S. Grover, Narendranath Epperla, Stephanie Mathews, Madelyn Burkart, Yazeed Sawalha, Brian T. Hill, Nilanjan Ghosh, Steven Park, David A. Bond, Kami J. Maddocks, Talha Badar, Timothy S. Fenske, Mehdi Hamadani, Jin Guo, Mary Malecek, Brad S. Kahl, Peter Martin, Kristie A. Blum, Christopher R. Flowers, Jonathon B. Cohen

Summary: The study analyzed clinical outcomes and survival predictors of patients with newly diagnosed mantle cell lymphoma treated with rituximab, finding that younger patients had significantly higher survival rates compared to older patients, and maintenance rituximab may mitigate the negative impact of age on survival.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

Article Oncology

Surveillance imaging during first remission in follicular lymphoma does not impact overall survival

Max L. Goldman, Jimmy J. Mao, Christopher S. Strouse, Wanqi Chen, Manali Rupji, Zhengjia Chen, Matthew J. Maurer, Oscar Calzada, Michael Churnetski, Christopher R. Flowers, James R. Cerhan, Brian K. Link, Carrie A. Thompson, Jonathon B. Cohen

Summary: The study found limited role for routine surveillance imaging in FL patients who complete front-line therapy. Future studies should evaluate which patients may benefit from a more aggressive surveillance approach and explore novel methods of relapse detection.

CANCER (2021)

Article Oncology

A prospective study on early PET/CT scans during the first cycle of salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma

Hua-Jay J. Cherng, Hubert H. Chuang, Raphael Steiner, Luis Fayad, Paolo Strati, Ranjit Nair, Fredrick Hagemeister, Loretta J. Nastoupil, Hun Ju Lee, Sattva S. Neelapu, Christopher R. Flowers, Felipe Samaniego, Maria Rodriguez, Homer A. Macapinlac, Lei Feng, Jason Westin

Summary: This study suggests that early PET/CT may predict treatment failure in patients with relapsed or refractory DLBCL, highlighting the potential benefits of early therapy changes for those who do not respond well to salvage chemotherapy. Further investigation into non-chemotherapy treatments based on early PET/CT findings could be valuable for future clinical trials.

LEUKEMIA & LYMPHOMA (2022)

Article Biochemistry & Molecular Biology

Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy

Melody Smith, Anqi Dai, Guido Ghilardi, Kimberly Amelsberg, Sean M. Devlin, Raymone Pajarillo, John B. Slingerland, Silvia Beghi, Pamela S. Herrera, Paul Giardina, Annelie Clurman, Emmanuel Dwomoh, Gabriel Armijo, Antonio L. C. Gomes, Eric R. Littmann, Jonas Schluter, Emily Fontana, Ying Taur, Jae H. Park, Maria Lia Palomba, Elizabeth Halton, Josel Ruiz, Tania Jain, Martina Pennisi, Aishat Olaide Afuye, Miguel-Angel Perales, Craig W. Freyer, Alfred Garfall, Shannon Gier, Sunita Nasta, Daniel Landsburg, James Gerson, Jakub Svoboda, Justin Cross, Elise A. Chong, Sergio Giralt, Saar Gill, Isabelle Riviere, David L. Porter, Stephen J. Schuster, Michel Sadelain, Noelle Frey, Renier J. Brentjens, Carl H. June, Eric G. Pamer, Jonathan U. Peled, Andrea Facciabene, Marcel R. M. van den Brink, Marco Ruella

Summary: This study investigated the changes in the intestinal microbiome of patients with B cell lymphoma and leukemia after receiving anti-CD19 CAR T cell therapy, and found that these changes are associated with clinical outcomes.

NATURE MEDICINE (2022)

Review Immunology

Custom CARs: Leveraging the Adaptability of Allogeneic CAR Therapies to Address Current Challenges in Relapsed/Refractory DLBCL

Nikeshan Jeyakumar, Melody Smith

Summary: Cellular therapies have revolutionized the treatment of relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). Autologous CAR T cells have shown promising results in achieving complete remission, but a significant portion of patients still relapse or progress. Allogeneic CAR T cells may offer a solution by addressing the limitations of autologous therapy and providing a more sustainable platform for cell therapies.

FRONTIERS IN IMMUNOLOGY (2022)

Article Hematology

Burnout in US hematologists and oncologists: impact of compensation models and advanced practice provider support

Alfred Ian Lee, Leah E. Masselink, Laura M. De Castro, Ariela L. Marshall, Nathan T. Connell, Georgette A. Dent, Josel Fritz, Morgan Homer, Tiffany L. Lucas, Rakhi P. Naik, Marquita Nelson, Casey L. O'Connell, Anita Rajasekhar, Robby J. Reynolds, Deva Sharma, Melody Smith, Lachelle D. Weeks, Clese E. Erikson

Summary: Burnout is common among hematologists and oncologists, but little is known about the impact of compensation and clinical support staff on burnout. A survey conducted by the American Society of Hematology in 2019 revealed that compensation plans solely based on clinical productivity were significantly associated with high burnout, while plans that included both productivity and salary showed no significant association. Female gender was associated with high burnout among academic physicians, and higher utilization of advanced practice providers was associated with lower burnout among community physicians.

BLOOD ADVANCES (2023)

Correction Biochemistry & Molecular Biology

Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy (March, 10.1038/s41591-022-01702-9, 2022)

Melody Smith, Anqi Dai, Guido Ghilardi, Kimberly V. Amelsberg, Sean M. Devlin, Raymone Pajarillo, John B. Slingerland, Silvia Beghi, Pamela S. Herrera, Paul Giardina, Annelie Clurman, Emmanuel Dwomoh, Gabriel Armijo, Antonio L. C. Gomes, Eric R. Littmann, Jonas Schluter, Emily Fontana, Ying Taur, Jae H. Park, Maria Lia Palomba, Elizabeth Halton, Josel Ruiz, Tania Jain, Martina Pennisi, Aishat Olaide Afuye, Miguel-Angel Perales, Craig W. Freyer, Alfred Garfall, Shannon Gier, Sunita Nasta, Daniel Landsburg, James Gerson, Jakub Svoboda, Justin Cross, Elise A. Chong, Sergio Giralt, Saar I. Gill, Isabelle Riviere, David L. Porter, Stephen J. Schuster, Michel Sadelain, Noelle Frey, Renier J. Brentjens, Carl H. June, Eric G. Pamer, Jonathan U. Peled, Andrea Facciabene, Marcel R. M. van den Brink, Marco Ruella

NATURE MEDICINE (2022)

Article Hematology

How I treat refractory CRS and ICANS after CAR T-cell therapy

Michael D. Jain, Melody Smith, Nirali N. Shah

Summary: The clinical use of CAR T-cell therapy is expanding due to increasing indications for treatment and new investigational products. Standard diagnostic criteria for CRS and ICANS, along with the use of tocilizumab and corticosteroids, have facilitated its widespread use. Preemptive interventions have improved safety, but persistent or progressive toxicities still pose challenges.

BLOOD (2023)

Editorial Material Hematology

Microbes matter in pediatric allo-HSCT

Melody Smith, Kate A. Markey

Summary: This study found that pediatric allo-HSCT patients with high microbial diversity prior to transplantation had longer overall survival and a lower incidence of acute GVHD. This is consistent with previous findings in adult allo-HSCT recipients. However, a key difference in this study is that the post-neutrophil engraftment microbiome was not associated with outcome, unlike in adults.

BLOOD (2023)

No Data Available